share_log

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Benzinga ·  May 1 20:06

Gainers

  • Akanda (NASDAQ:AKAN) shares moved upwards by 69.1% to $0.16 during Wednesday's pre-market session. The company's market cap stands at $1.8 million.
  • NanoVibronix (NASDAQ:NAOV) shares moved upwards by 25.17% to $0.92. The market value of their outstanding shares is at $2.5 million.
  • Predictive Oncology (NASDAQ:POAI) shares increased by 23.4% to $1.74. The market value of their outstanding shares is at $7.0 million.
  • Lucy Scientific Discovery (NASDAQ:LSDI) shares moved upwards by 19.0% to $0.99. The company's market cap stands at $1.7 million.
  • Emergent BioSolutions (NYSE:EBS) stock moved upwards by 18.08% to $2.22. The company's market cap stands at $116.3 million. As per the press release, Q1 earnings came out today.
  • IGC Pharma (AMEX:IGC) stock moved upwards by 17.15% to $0.64. The market value of their outstanding shares is at $42.4 million.

Losers

  • CVRx (NASDAQ:CVRX) stock fell 20.5% to $12.33 during Wednesday's pre-market session. The company's market cap stands at $266.2 million. As per the press release, Q1 earnings came out yesterday.
  • NRX Pharmaceuticals (NASDAQ:NRXP) shares declined by 18.22% to $2.11. The company's market cap stands at $22.1 million.
  • BiomX (AMEX:PHGE) shares decreased by 14.41% to $0.41. The market value of their outstanding shares is at $22.6 million.
  • Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock decreased by 11.8% to $1.87. The company's market cap stands at $2.4 million.
  • CVS Health (NYSE:CVS) stock decreased by 11.67% to $59.81. The market value of their outstanding shares is at $75.3 billion. As per the news, the Q1 earnings report came out today.
  • Barinthus Biotherapeutics (NASDAQ:BRNS) stock decreased by 8.79% to $1.87. The market value of their outstanding shares is at $72.7 million.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment